Dyne Therapeutics, Inc. entered into a Second Amendment to its Loan and Security Agreement with Hercules Capital, Inc. and other lenders on June 16, 2026, expanding its debt facility to an aggregate of up to $400.0 million. The amendment added two $50.0 million tranches and increased a final tranche by $25.0 million, while also reducing the minimum cash covenant from 60% to 40% of outstanding obligations. The company borrowed $50.0 million on the closing date, bringing its outstanding principal to $200.0 million. Dyne Therapeutics, Inc. is a biotechnology company focused on developing therapies for neuromuscular diseases.
